Nursing women (lactating females are eligible provided that they agree not to breast feed while taking lenalidomide)
Pregnant or breast feeding females (lactating females must agree not to breast feed while taking the study drugs)
Female subject is pregnant or breast-feeding; lactating females must agree not to breastfeed while taking lenalidomide
Pregnant females; (lactating females must agree not to breast feed while taking ibrutinib)
Pregnant or breast feeding females (lactating females must agree not to breast feed while taking lenalidomide).
Nursing women (lactating females are eligible provided that they agree not to breast feed while taking lenalidomide)
Women must agree not to breast feed while on study
Females who are pregnant, test positive for pregnancy, or are breast-feeding during the Screening period, or intend to become pregnant or breast-feed during the course of the study or within  days after last dose of study drug
Breast feeding (if lactating, must agree not to breast feed while taking lenalidomide); breastfeeding should be discontinued if the mother is treated with lenalidomide
Pregnant or need to breast feed during the study period
Females who are pregnant, test positive for pregnancy, or are breast-feeding during the Screening period, or intend to become pregnant or breast-feed during the course of the study or within  days after last dose of study drug
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant or breast-feeding females; (lactating females must agree not to breast-feed while taking lenalidomide)
Pregnant or breast-feeding females; lactating females must agree not to breast-feed while taking lenalidomide
Breast feeding (if lactating, must agree not to breast feed while taking pomalidomide)
Pregnant or breast feeding females (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant females; (lactating females must agree not to breast feed while taking the study medications)
Pregnant or lactating; women should not breast feed during the interval from study entry to one\r\nyear post-transplant
Pregnant or breast-feeding females. (Lactating females must agree not to breast feed while taking lenalidomide).
Pregnant or lactating females who chose to breast feed
Female participants pregnant or breast-feeding; pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with lenalidomide; these potential risks may also apply to other agents used in this study; lactating females must agree not to breast feed while taking lenalidomide
Subject is pregnant or breast-feeding. Women must not breast-feed until at  months after completion of study participation..
Patients who wish to breast-feed during treatment
Pregnant or breast-feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant females (lactating females must agree not to breast feed while taking carfilzomib, lenalidomide or romidepsin)
Women must agree not to breast feed
Women must not breast-feed while taking the study medications
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking pomalidomide)
Pregnant or breastfeeding women; (lactating women must agree not to breast feed while taking -azacitidine)
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant or breast feeding females.(Lactating females must agree not to breast feed while taking lenalidomide).
Pregnant or breast-feeding females; (lactating females must agree not to breast feed while taking Revlimid)
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide or azacitidine)
Pregnant or breast feeding females (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking ibrutinib or idelalisib)
Pregnant or breast feeding females (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
Pregnant or breast feeding females (lactating females must agree not to breast feed while taking ipilimumab)
Pregnant or breast feeding females; lactating females must agree not to breast feed while taking lenalidomide
Pregnant or breast feeding females; (lactating females must agree not to breast feed while taking lenalidomide)
Women must agree not to breast feed while on abemaciclib treatment and for at least three months following the last dose of study therapy
Women must not breast-feed while taking the study medications
Women must not breast-feed while taking the study medications